The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
German Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective.
The European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.
In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.
Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.
Syngenta has announced to leverage Biotalys’ AGROBODY technology platform to expand its biocontrol pipeline.
Phialogics AG has got a €600,000 pre-seed financing from German HTGF to validate its approach to rebalance the immune system of people with auto-immune diseases.
European life sciences venture capital company Forbion has raised two oversubscribed funds totalling €1.35 bn.
German radiopharmaceuticals developer Ariceum Therapeutics has raised a further €22.75m extension of its €25m Series A financing announced in June 2022.